Astria Therapeutics, Inc. (ATXS) Reports Q3 Loss, Misses Revenue Estimates

Core Insights - Astria Therapeutics reported a quarterly loss of $0.55 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.41, marking an earnings surprise of -34.15% [1] - The company generated revenues of $0.71 million for the quarter ended September 2025, missing the Zacks Consensus Estimate by 95.59%, compared to zero revenues a year ago [2] - The stock has increased approximately 39.9% year-to-date, outperforming the S&P 500's gain of 16.4% [3] Earnings Outlook - The current consensus EPS estimate for the upcoming quarter is -$0.59 on $2 million in revenues, and for the current fiscal year, it is -$2.09 on $17 million in revenues [7] - The estimate revisions trend for Astria Therapeutics was mixed ahead of the earnings release, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market [6] Industry Context - The Medical - Biomedical and Genetics industry, to which Astria Therapeutics belongs, is currently in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Aytu BioPharma Inc., another company in the same industry, is expected to report a quarterly loss of $0.06 per share, reflecting a year-over-year change of +70% [9]